AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Glyni M 80mg/500mg Tablet

Prescription Icon
Prescription Required

Marketer

Aronex Life Sciences Pvt Ltd

Salt Composition

Gliclazide (80mg) + Metformin (500mg)

Overview Glyni M 80mg/500mg Tablet

Metformin/Glibenclamide 80mg/500mg tablets are classified as antidiabetic medications. This dual-drug formulation manages type 2 diabetes in adults by regulating blood glucose. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on blood sugar monitoring. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. Remember, this medication complements a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your doctor. Lifestyle choices significantly impact diabetes control. Common side effects include hypoglycemia (low blood sugar), characterized by sweating, dizziness, headache, and tremors; constipation; and vomiting. Maintain regular mealtimes and carry a readily available fast-acting glucose source (e.g., sugary snacks, fruit juice). Alcohol consumption elevates hypoglycemia risk and should be avoided. Additional possible side effects encompass altered taste, nausea, diarrhea, abdominal discomfort, headache, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Individuals with a history of cardiovascular disease should inform their physician prior to commencing treatment. Pregnancy or breastfeeding necessitates medical consultation before use. Regular blood glucose monitoring is essential, along with potential blood tests to track blood cell counts and liver function.

Uses of Glyni M 80mg/500mg Tablet

Non-insulin-dependent diabetes

Major Benefits of Glyni M 80mg/500mg Tablet:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Ingest the Glyni M 80mg/500mg Tablet whole; avoid chewing, crushing, or breaking it. Administer this medication with food.

Common Side effects of Glyni M 80mg/500mg Tablet:

  • Hypoglycemia (low blood glucose level)
  • Headache
  • Dizziness
  • Diarrhea
  • Upper respiratory tract infection
  • Nausea
  • Flatulence
  • Constipation

How to use Glyni M 80mg/500mg Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet without chewing, crushing, or breaking it. Glyni M 80mg/500mg tablets should be administered with a meal.

How Glyni M 80mg/500mg Tablet works:

Gliclazide and metformin, at doses of 80mg and 500mg respectively, are combined in Glyni M tablets to manage blood sugar levels.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Glyni M 80mg/500mg tablets with alcohol is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Use of Glyni M 80mg/500mg tablets is contraindicated during pregnancy due to established risks to fetal development. In exceptional circumstances involving life-threatening conditions, a physician may prescribe it if the potential benefits outweigh the hazards. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Glyni M 80mg/500mg tablets while breastfeeding is likely inadvisable. Preliminary human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood sugar levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with kidney impairment should use Glyni M 80mg/500mg tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates Glyni M 80mg/500mg tablet use. Physician consultation is necessary. Kidney function should be regularly monitored during treatment with this medication.

LiverLiverCAUTION

Patients with liver impairment should use Glyni M 80mg/500mg Tablets cautiously, potentially requiring dosage modification. A physician's consultation is advised. In individuals with mild to moderate hepatic dysfunction, Glyni M 80mg/500mg Tablets are typically initiated at a reduced dosage; however, their use is contraindicated in those with severe liver disease.

What if you forget to take Glyni M 80mg/500mg Tablet :

Should you forget a Glyni M 80mg/500mg Tablet dose, administer it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Glyni M 80mg/500mg Tablet

LabelValue
Potential for Dependence None.
Treatment Category Medication for diabetes

FAQs on Glyni M 80mg/500mg Tablet

Glyni M 80mg/500mg tablets contain gliclazide and metformin, two medications used together to manage type 2 diabetes mellitus. This treatment improves blood sugar control in adults when combined with a healthy diet and regular physical activity. Gliclazide enhances insulin secretion from the pancreas, reducing blood glucose. Metformin decreases hepatic glucose production and increases insulin responsiveness. This dual medication is unsuitable for managing type 1 diabetes.
Glyni M 80mg/500mg tablets may cause frequent side effects such as low blood sugar (hypoglycemia), changes in taste perception, queasiness, abdominal discomfort, loose stools, cephalalgia, and upper respiratory infections. Rare but potentially severe adverse reactions, including lactic acidosis, are also possible. Prolonged administration might result in vitamin B12 insufficiency.
Glyni M 80mg/500mg Tablets can induce hypoglycemia, characterized by low blood sugar. This may manifest as nausea, headache, irritability, hunger, sweating, dizziness, tachycardia, and anxiety or tremors. The risk increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Consequently, consistent blood glucose monitoring is crucial. Carrying glucose tablets, honey, or fruit juice is advisable.
Glyni M 80mg/500mg Tablets can cause lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. This adverse reaction, also termed metformin-associated lactic acidosis (MALA), is infrequent but a potential consequence of metformin use. To minimize risk, its use is contraindicated in individuals with pre-existing kidney impairment, the elderly, and those consuming substantial alcohol. Symptoms such as muscular pain or weakness, vertigo, fatigue, cold extremities, dyspnea, nausea, emesis, abdominal discomfort, or bradycardia warrant immediate cessation of Glyni M 80mg/500mg Tablet intake and prompt medical attention.
Glyni M 80mg/500mg Tablet may induce vitamin B12 deficiency with prolonged administration. This deficiency arises from the medication's interference with gastric vitamin B12 absorption. Left unaddressed, this can lead to anemia, neurological complications such as paresthesia in the extremities, weakness, urinary dysfunction, cognitive changes, and gait instability. Preventive strategies proposed by some investigators include annual supplemental vitamin B12 intake.
Patients with hypersensitivity to any ingredient or inactive component within Glyni M 80mg/500mg Tablet should not use this medication. Similarly, its use is contraindicated in individuals experiencing moderate to severe renal impairment or those with pre-existing metabolic acidosis, such as diabetic ketoacidosis.
Consuming alcohol concurrently with Glyni M 80mg/500mg tablets is inadvisable. This combination risks dangerously reducing blood sugar (hypoglycemia) and elevates the probability of lactic acidosis.
Glyni M 80mg/500mg tablets contain gliclazide and metformin, acting together to manage type 2 diabetes mellitus. This dual-action medication helps regulate blood sugar in adults, complemented by a suitable diet and exercise program. Gliclazide stimulates insulin secretion from the pancreas, reducing blood glucose. Metformin decreases hepatic glucose production and enhances insulin effectiveness. This formulation is unsuitable for type 1 diabetes.
Glyni M 80mg/500mg tablets may cause common adverse reactions such as low blood sugar (hypoglycemia), changes in taste perception, nausea, abdominal discomfort, diarrhea, headache, and upper respiratory infections. Rare but potentially serious side effects, including lactic acidosis, are also possible. Prolonged treatment may result in vitamin B12 deficiency.
Glyni M 80mg/500mg Tablets can induce hypoglycemia, characterized by low blood sugar. Manifestations of low blood sugar include nausea, headache, irritability, hunger, sweating, dizziness, tachycardia, and feelings of anxiety or tremor. The likelihood of hypoglycemia increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Consequently, regular blood glucose monitoring is crucial. Carrying readily available glucose sources, such as glucose tablets, honey, or fruit juice, is advisable.
Glyni M 80mg/500mg Tablets can cause lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed metformin-associated lactic acidosis (MALA), this is an infrequent complication of metformin use. Risk factors include pre-existing kidney impairment, advanced age, and significant alcohol consumption. Symptoms may encompass muscle aches or weakness, lightheadedness, fatigue, cold extremities, respiratory distress, nausea, vomiting, abdominal pain, and bradycardia. Should these symptoms arise, discontinue Glyni M 80mg/500mg Tablet use and seek immediate medical attention.
Prolonged Glyni M 80mg/500mg Tablet use can indeed lead to vitamin B12 deficiency. This is because the medication hinders the stomach's absorption of vitamin B12. Left unaddressed, this deficiency may result in anemia, neurological issues such as tingling and numbness in the extremities, muscle weakness, urinary dysfunction, cognitive impairment, and gait instability. Preventive measures proposed by some studies include annual supplemental vitamin B12 intake.
Patients with hypersensitivity to any ingredient or inactive substance in Glyni M 80mg/500mg Tablets should not use this medication. Similarly, its use is contraindicated in individuals with moderate to severe renal impairment or pre-existing metabolic acidosis, such as diabetic ketoacidosis.
Consuming alcohol concurrently with Glyni M 80mg/500mg Tablet is inadvisable. This combination may lead to dangerously low blood glucose and heighten the risk of lactic acidosis.
Glyni M 80mg/500mg Tablet
42
MRP 51
17% off